Drug Trial Radar · NCT06047379
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
134
Planned (sponsor's estimate)
Start
Nov 1, 2023
Primary completion
Feb 28, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Neonc Technologies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b.
Conditions
- Diffuse Astrocytoma, IDH-Mutant
- Glioblastoma, IDH-wildtype
- Brain Metastases, Adult
- Cervical Cancer
- Colorectal Cancer
- Esophageal Cancer
- Esophageal Squamous Cell Carcinoma
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Head and Neck Squamous Cell Carcinoma
- Melanoma
- Merkel Cell Carcinoma
- Microsatellite Instability-High Solid Malignant Tumor
- Mismatch Repair Deficient Solid Malignant Tumor
- Microsatellite Instability-High Colorectal Cancer
- Mismatch Repair Deficient Colorectal Cancer
- Non-small Cell Lung Cancer
- Renal Cell Carcinoma
- Small Cell Lung Cancer
- Squamous Cell Carcinoma
- Urothelial Carcinoma
Interventions
NEO212 Oral CapsuleDrug
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
IpilimumabDrug
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
PembrolizumabDrug
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
NivolumabDrug
Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
RegorafenibDrug
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
CarboplatinDrug
Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
PaclitaxelDrug
Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
FOLFIRI ProtocolDrug
FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs: FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
BevacizumabDrug
Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brainTime frame: 6 months
- Phase 1: Identify the maximum tolerated dose (MTD) of NEO212Time frame: 6 months
- Phase 1: Determine the recommended Phase 2 dose (RP2D) of NEO212Time frame: 6 months
- Phase 2a: Assess the safety and tolerability of orally administered NEO212 in combination with select SOC regimens following a standard 3+3 design in patients with select solid tumors with uncontrolled metastases to the brainTime frame: 6 months
- Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype.Time frame: 6 months
- Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors with uncontrolled metastases to the brain.Time frame: 6 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Precision NextGen Oncology
Beverly Hills, California · Recruiting
OPN Healthcare, Inc
Glendale, California · Recruiting
University of Southern California
Los Angeles, California · Recruiting
MDR Core Network
Boynton Beach, Florida · Recruiting
Tufts Medical Center
Boston, Massachusetts · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Baylor, Scott and White Research Institute
Dallas, Texas · Recruiting
Northwest Medical Specialties
Tacoma, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.